CD4+ Counts before and after Switching to Monoclonal High-Purity Factor VIII Concentrate in HIV-Infected Haemophilic Patients

Summary

Allogenic proteins that contaminate intermediate purity clotting factor concentrates may activate the immune system of HIV-infected haemophilic patients. In 37 haemophilic patients infected with HIV who had originally been treated with intermediate purity factor VIII concentrate and then changed to monoclonally-purified high purity factor VIII concentrate the rates of CD4+ decline (10⁹/1 per year) were 0.06 before and 0.02 after a switch to high purity products (p = 0.01). The median follow-up of patients after the switch to high purity products was 1.7 years (range 0.2 to 3 years). This significant change in the rate of CD4 decline was independent of the starting CD4 count, age and antiretroviral therapy. This result is consistent with those from randomised trials of the introduction of high-purity concentrate. Given the strong association between the CD4+ count and survival, treatment with high purity rather than intermediate purity clotting factor concentrate may confer a survival benefit for HIV-infected haemophilic patients.

• References

• 1 Brettler DB, Levine PH. Factor concentrates for treatment of haemophilia: which one to choose?. Blood 1989; 73: 2067-2073
• 2 Mannucci PM. Modem treatment of haemophilia: From the shadows towards the light. Thromb Haemost 1993; 70 (01) 17-23
• 3 Brettler DB, Forsberg AD, Levine PH, Petillo J, Lamon K, Sullivan JL. Factor VIII :C concentrate purified from plasma using monoclonal antibodies: human studies. Blood 1989; 3: 1859-1863
• 4 Goldsmith JM, Deutsche J, Tang M, Green D. CD4 cells in HIV-1 infected hemophiliacs: effects of factor VIII concentrates. Thromb Haemost 1991; 66: 415-419
• 5 Fukutake K, Hada M, Ikematsu S. et al Multicenter study on the influence of long-term continuous use of ultrapurified factor VIII preparation on the immunological status of HIV-infected and non-infected hemophilia A patients. XlXth International Congress of the World Federation of Hemophilia 1990 (abstr)
• 6 Rocino A, Miraglia E, Mastrullo L, Quirino AA, Ziello L, de Biasi R. Prospective controlled trial of an ultra-pure Factor VIII Concentrate to evaluate the effects on the immune status of HIV antibody positive hemophilia patients (preliminary results). Acta Toxicologica et Therapeutica 1990; XI: 49-58
• 7 de Biasi R, Rocino A, Miraglia E, Mastrullo L, Quirino AA. The Impact of a Very High Purity Factor VIII Concentrate on the Immune System of Human Immunodeficiency virus-infected hemophiliacs: a randomised, prospective, two-year comparison with an intermediate purity concentrate. Blood 1991; 78: 1919-1922
• 8 Seremetis S, Aledort LM, Bergman G, Bona R, Bray G, Brettler D, Eyster ME, Kessler C, Lan T, Lusher J, Rickies F. Three-year randomised study of high-purity or intermediate purity factor VIII concentrates in symptom-free HIV-seropositive haemophiliacs: Effects on immune status. Lancet 1993; 342: 700-703
• 9 Hilgartner MW, Buckley JD, Openskaliski EA, Pike MC, Mosley JW. Purity of factor VIII concentrates and serial CD4 counts. Lancet 1993; 341: 1373-1374
• 10 Mannucci PM, Gringeri A, de Biasi R, Bando F, Morfini M, Ciavarella N. Immune status of asymptomatic HIV-infected Hemophiliacs: Randomised, prospective, two-year comparison of treatment with a high-purity or an intermediate purity factor VIII concentrate. Thromb Haemost 1992; 67: 310-313
• 11 UK Regional Haemophilia Centre Directors Committee. Recommendations on Choice of Therapeutic Products for the Treatment of Patients with Haemophilia A, Haemophilia B and Von Willebrand,s Disease. Blood Coagulation And Fibrinolysis 1992; 3: 205-214
• 12 Vermylen J, Briët E. Factor VIII preparations: need for prospective phar-macovigilance. Lancet 1993; 342: 693-694
• 13 Lee CA, Phillips AN, Elford J, Janossy G, Griffiths P, Kemoff P. Progression of HIV disease in a haemophilic cohort followed for 11 years and the effect of treatment. BMJ 1991; 303: 1093-1096
• 14 Lee CA, Phillips A, Elford J, Miller EJ, Bofill M, Griffiths PD, Kernoff PBA. The natural history of human immunodeficiency virus infection in a haemophilic cohort. Brit J Haematol 1989; 73: 228-234
• 15 Phillips AN, Lee CA, Elford J, Janossy G, Timms A, Bofill M, Kernoff PBA. Serial CD4 lymphocyte counts and development of AIDS. Lancet 1991; 337: 389-392
• 16 Centers for Disease Control: Revision of the CDC surveillance case definition for acquired immunodeficiency syndrome. MMWR 1987; 36 (Suppl) (Suppl. 15) 1-15
• 17 Bofill M, Janossy G, Lee CA, Mac Donald-Burns D, Phillips AN, Sabin C, Timms A, Johnson MA, Kemoff PBA. Laboratory control values for CD4 and CD8 T lymphocytes. Implications for HIV-1 diagnosis. Clin Exp Immunol 1992; 88: 243-252
• 18 Yarchoan R, Venzon DJ, Pluda JM, Lietzau J, Wyvill KM, Tsiatis AA, Steinberg SM, Broder S. CD4 count and the risk for death in patients infected with HIV receiving antiretroviral therapy. Ann Intern Med 1991; 115: 184-189
• 19 Phillips AN, Elford J, Sabin C, Bofill M, Janossy G, Lee CA. Immunodeficiency and the risk of death in HIV infection. JAMA 1992; 268: 2662-2666
• 20 Evans JA, Pasi KJ, Williams MD, Hill FGH. Consistently normal CD4+, CD8+ levels in haemophilic boys only treated with a virally safe factor VIII concentrate (BPL 8Y). Br J Haematol 1991; 79: 457-461
• 21 Wadhwa M, Dilger P, Thorpe R, Borrowcliffe T, Mire-Sluis A. Identification of TGF-β₁, as an immunosuppressant contaminant in factor VIII concentrates. Thromb Haemost 1993; 69: 851
• 22 Lazardins JK, Klimkait T, Woods-Cook K, Walker M, Alteri E, Cox D, Ceretti N, Shipman R, Bilbe G, McMaster G. In vitro effect of transforming growth factor-β on progression of HIV-1 infection in primary mononuclear phagocytes. J Immunol 1991; 147: 1201-1207
• 23 Multi-cohort Analysis Project workshop. Extending public health surveillance of HIV disease. Stats in Med 1993; 12: 2065-2085